Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015.

Somers EC, Lee J, Hassett AL, Zick SM, Harlow SD, Helmick CG, Barbour KE, Gordon C, Brummett CM, Minhas D, Padda A, Wang L, McCune WJ, Marder W.

MMWR Morb Mortal Wkly Rep. 2019 Sep 27;68(38):819-824. doi: 10.15585/mmwr.mm6838a2.

2.

West Nile encephalitis mimicking neuropsychiatric lupus in a patient with systemic lupus erythematosus.

Iyer NR, McCune WJ, Wallace BI.

BMJ Case Rep. 2019 Jul 24;12(7). pii: e229537. doi: 10.1136/bcr-2019-229537.

PMID:
31345830
3.

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program.

Charoenwoodhipong P, Harlow SD, Marder W, Hassett AL, McCune WJ, Gordon C, Helmick CG, Barbour KE, Wang L, Mancuso P, Somers EC, Zick SM.

Arthritis Care Res (Hoboken). 2019 May 10. doi: 10.1002/acr.23925. [Epub ahead of print]

PMID:
31074595
4.

Treatment of primary and secondary immune thrombocytopenia.

Kado R, McCune WJ.

Curr Opin Rheumatol. 2019 May;31(3):213-222. doi: 10.1097/BOR.0000000000000599.

PMID:
30920453
5.

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.

Arthritis Rheumatol. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5.

6.

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Vreede AP, Bockenstedt PL, McCune WJ, Knight JS.

Curr Opin Rheumatol. 2019 May;31(3):231-240. doi: 10.1097/BOR.0000000000000595.

7.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

8.

Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus.

Bhattacharya J, Pappas K, Toz B, Aranow C, Mackay M, Gregersen PK, Doumbo O, Traore AK, Lesser ML, McMahon M, Utset T, Silverman E, Levy D, McCune WJ, Jolly M, Wallace D, Weisman M, Romero-Diaz J, Diamond B.

Mol Med. 2018 Jun 1;24(1):24. doi: 10.1186/s10020-018-0019-4.

9.

The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.

Sunkara B, Roofeh D, Silver S, Pearson TL, Ettel M, McCune WJ.

Lupus. 2018 Jul;27(8):1383-1386. doi: 10.1177/0961203318768884. Epub 2018 Apr 9.

PMID:
29631513
10.

The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Littlejohn E, Marder W, Lewis E, Francis S, Jackish J, McCune WJ, Somers EC.

Lupus. 2018 Jun;27(7):1123-1129. doi: 10.1177/0961203318763732. Epub 2018 Mar 16.

11.

Mycophenolate mofetil, for rheumatic diseases: should we monitor the area under the curve?

McCune WJ, Al Abbas M.

Curr Opin Rheumatol. 2018 May;30(3):229-230. doi: 10.1097/BOR.0000000000000501. No abstract available.

PMID:
29538009
12.

Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.

Abdulaziz N, Shah AR, McCune WJ.

Curr Opin Rheumatol. 2018 May;30(3):249-255. doi: 10.1097/BOR.0000000000000500. Review.

PMID:
29517495
13.

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

Rhee RL, Davis JC, Ding L, Fervenza FC, Hoffman GS, Kallenberg CGM, Langford CA, McCune WJ, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Stone JH, Merkel PA.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.

14.

CD4+CD28+KIR+CD11ahi T cells correlate with disease activity and are characterized by a pro-inflammatory epigenetic and transcriptional profile in lupus patients.

Gensterblum E, Renauer P, Coit P, Strickland FM, Kilian NC, Miller S, Ognenovski M, Wren JD, Tsou PS, Lewis EE, Maksimowicz-McKinnon K, McCune WJ, Richardson BC, Sawalha AH.

J Autoimmun. 2018 Jan;86:19-28. doi: 10.1016/j.jaut.2017.09.011. Epub 2017 Oct 20.

15.

Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases.

Nagaraja V, Mara C, Khanna PP, Namas R, Young A, Fox DA, Laing T, McCune WJ, Dodge C, Rizzo D, Almackenzie M, Khanna D.

Qual Life Res. 2018 Mar;27(3):755-764. doi: 10.1007/s11136-017-1709-z. Epub 2017 Oct 5.

16.

Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.

Singer O, McCune WJ.

Curr Opin Rheumatol. 2017 May;29(3):248-253. doi: 10.1097/BOR.0000000000000382. Review.

PMID:
28306595
17.

Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy.

Kado R, Sanders G, McCune WJ.

Curr Opin Rheumatol. 2017 May;29(3):228-233. doi: 10.1097/BOR.0000000000000377. Review.

PMID:
28240614
18.

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clain JM, Hummel AM, Stone JH, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Specks U; WGET and RAVE-ITN Research Groups.

Clin Exp Immunol. 2017 Apr;188(1):174-181. doi: 10.1111/cei.12925. Epub 2017 Feb 7.

19.

Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.

Grenn RC, Yalavarthi S, Gandhi AA, Kazzaz NM, Núñez-Álvarez C, Hernández-Ramírez D, Cabral AR, McCune WJ, Bockenstedt PL, Knight JS.

Ann Rheum Dis. 2017 Feb;76(2):450-457. doi: 10.1136/annrheumdis-2016-209442. Epub 2016 Jul 18.

20.

Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares.

Coit P, Dozmorov MG, Merrill JT, McCune WJ, Maksimowicz-McKinnon K, Wren JD, Sawalha AH.

Arthritis Rheumatol. 2016 Sep;68(9):2200-9. doi: 10.1002/art.39720.

21.

Suppression of normal immune responses after treatment with rituximab.

Kado R, Sanders G, McCune WJ.

Curr Opin Rheumatol. 2016 May;28(3):251-8. doi: 10.1097/BOR.0000000000000272. Review.

PMID:
27027812
22.

Treatment of catastrophic antiphospholipid syndrome.

Kazzaz NM, McCune WJ, Knight JS.

Curr Opin Rheumatol. 2016 May;28(3):218-27. doi: 10.1097/BOR.0000000000000269. Review.

23.

X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, Lazaro S, Weaver CA, Ice JA, Adler AJ, Chodosh J, Radfar L, Rasmussen A, Stone DU, Lewis DM, Li S, Koelsch KA, Igoe A, Talsania M, Kumar J, Maier-Moore JS, Harris VM, Gopalakrishnan R, Jonsson R, Lessard JA, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Illei GG, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng WF, Nordmark G, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Segal BM, Vyse TJ, Wahren-Herlenius M, Witte T, Pons-Estel B, Alarcon-Riquelme ME, Guthridge JM, James JA, Lessard CJ, Kelly JA, Thompson SD, Gaffney PM, Montgomery CG, Edberg JC, Kimberly RP, Alarcón GS, Langefeld CL, Gilkeson GS, Kamen DL, Tsao BP, McCune WJ, Salmon JE, Merrill JT, Weisman MH, Wallace DJ, Utset TO, Bottinger EP, Amos CI, Siminovitch KA, Mariette X, Sivils KL, Harley JB, Scofield RH.

Arthritis Rheumatol. 2016 May;68(5):1290-1300. doi: 10.1002/art.39560.

24.

Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival.

Kazzaz NM, Coit P, Lewis EE, McCune WJ, Sawalha AH, Knight JS.

Lupus Sci Med. 2015 Sep 23;2(1):e000117. doi: 10.1136/lupus-2015-000117. eCollection 2015.

25.

DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus.

Renauer P, Coit P, Jeffries MA, Merrill JT, McCune WJ, Maksimowicz-McKinnon K, Sawalha AH.

Lupus Sci Med. 2015 Sep 15;2(1):e000101. doi: 10.1136/lupus-2015-000101. eCollection 2015.

26.

Utility and Associated Risk of Pulmonary Embolism Computed Tomography Scans in the Michigan Lupus Cohort.

Kado R, Siegwald E, Lewis E, Goodsitt MM, Christodoulou E, Kazerooni E, McCune WJ.

Arthritis Care Res (Hoboken). 2016 Mar;68(3):406-11. doi: 10.1002/acr.22684.

27.

A highlight from the LUPUS 2014 meeting: eight great ideas.

Buyon JP, Cohen P, Merrill JT, Gilkeson G, Kaplan M, James J, McCune WJ, Bernatsky S, Elkon K.

Lupus Sci Med. 2015 Jun 30;2(1):e000087. doi: 10.1136/lupus-2015-000087. eCollection 2015. Review.

28.

Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells.

Coit P, Renauer P, Jeffries MA, Merrill JT, McCune WJ, Maksimowicz-McKinnon K, Sawalha AH.

J Autoimmun. 2015 Jul;61:29-35. doi: 10.1016/j.jaut.2015.05.003. Epub 2015 May 23.

29.

Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program.

Housey M, DeGuire P, Lyon-Callo S, Wang L, Marder W, McCune WJ, Helmick CG, Gordon C, Dhar JP, Leisen J, Somers EC.

Am J Public Health. 2015 May;105(5):e74-9. doi: 10.2105/AJPH.2014.302423. Epub 2015 Mar 19.

30.

Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?

McCune WJ, Gonzalez-Rivera T.

Curr Opin Rheumatol. 2015 May;27(3):213-5. doi: 10.1097/BOR.0000000000000173. No abstract available.

PMID:
25784384
31.

Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies.

Marder W, Romero VC, Ganser MA, Hyzy MA, Gordon C, McCune WJ, Somers EC.

Lupus Sci Med. 2014 Jul 15;1(1):e000034. doi: 10.1136/lupus-2014-000034. eCollection 2014.

32.

Diminished white matter integrity in patients with systemic lupus erythematosus.

Schmidt-Wilcke T, Cagnoli P, Wang P, Schultz T, Lotz A, Mccune WJ, Sundgren PC.

Neuroimage Clin. 2014 Jul 10;5:291-7. doi: 10.1016/j.nicl.2014.07.001. eCollection 2014.

33.

Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's).

Tomasson G, Davis JC, Hoffman GS, McCune WJ, Specks U, Spiera R, St Clair EW, Stone JH, Merkel PA.

Arthritis Rheumatol. 2014 Feb;66(2):428-32. doi: 10.1002/art.38248.

34.

Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program.

Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, Wing JJ, Dhar JP, Leisen J, Shaltis D, McCune WJ.

Arthritis Rheumatol. 2014 Feb;66(2):369-78. doi: 10.1002/art.38238.

35.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

36.

Reduced Insular Glutamine and N-acetylaspartate in systemic lupus erythematosus: a single-voxel (1)H-MR spectroscopy study.

Cagnoli P, Harris RE, Frechtling D, Berkis G, Gracley RH, Graft CC, Lowe SE, Chenevert TL, McCune WJ, Gebarski S, Sundgren PC.

Acad Radiol. 2013 Oct;20(10):1286-96. doi: 10.1016/j.acra.2013.07.011.

37.

The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus.

Zhao W, Berthier CC, Lewis EE, McCune WJ, Kretzler M, Kaplan MJ.

Clin Immunol. 2013 Oct;149(1):119-32. doi: 10.1016/j.clim.2013.07.002. Epub 2013 Jul 20.

38.

Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients.

Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, Merrill JT, McCune WJ, Sawalha AH.

J Autoimmun. 2013 Jun;43:78-84. doi: 10.1016/j.jaut.2013.04.003. Epub 2013 Apr 24.

39.

A 50-year old woman with nasal congestion, cough, and dyspnea.

Ross JA, McCune WJ, Sanders G.

Allergy Asthma Proc. 2013 Mar-Apr;34(2):188-92. doi: 10.2500/aap.2013.34.3637.

PMID:
23484897
40.

Overexpression of X-linked genes in T cells from women with lupus.

Hewagama A, Gorelik G, Patel D, Liyanarachchi P, McCune WJ, Somers E, Gonzalez-Rivera T; Michigan Lupus Cohort, Strickland F, Richardson B.

J Autoimmun. 2013 Mar;41:60-71. doi: 10.1016/j.jaut.2012.12.006. Epub 2013 Feb 19.

41.

In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus.

Marder W, Ganser MA, Romero V, Hyzy MA, Gordon C, McCune WJ, Somers EC.

Arthritis Care Res (Hoboken). 2013 May;65(5):759-66. doi: 10.1002/acr.21888.

42.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

43.

Perfusion-weighted MR imaging in cerebral lupus erythematosus.

Wang PI, Cagnoli PC, McCune WJ, Schmidt-Wilcke T, Lowe SE, Graft CC, Gebarski SS, Chenevert TL, Khalatbari S, Myles JD, Watcharotone K, Cronin P, Sundgren PC.

Acad Radiol. 2012 Aug;19(8):965-70. doi: 10.1016/j.acra.2012.03.023. Epub 2012 May 17.

44.

Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.

Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, Kazerooni EA, McCune WJ, Kaplan MJ.

PLoS One. 2012;7(5):e37000. doi: 10.1371/journal.pone.0037000. Epub 2012 May 14.

45.

Changes in regional brain morphology in neuropsychiatric systemic lupus erythematosus.

Cagnoli PC, Sundgren PC, Kairys A, Graft CC, Clauw DJ, Gebarski S, McCune WJ, Schmidt-Wilcke T.

J Rheumatol. 2012 May;39(5):959-67. doi: 10.3899/jrheum.110833. Epub 2012 Apr 1.

PMID:
22467931
46.

Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity.

Sawalha AH, Wang L, Nadig A, Somers EC, McCune WJ; Michigan Lupus Cohort, Hughes T, Merrill JT, Scofield RH, Strickland FM, Richardson B.

J Autoimmun. 2012 May;38(2-3):J216-22. doi: 10.1016/j.jaut.2011.11.008. Epub 2012 Feb 3.

47.

Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.

Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, Christman GM, Somers EC.

Gynecol Endocrinol. 2012 Aug;28(8):624-7. doi: 10.3109/09513590.2011.650752. Epub 2012 Feb 2.

48.

Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).

Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, Spiera RF, Davis JC Jr, McCune WJ, Ytterberg SR, St Clair EW, Allen NB, Specks U, Stone JH; WGET Research Group.

Arthritis Care Res (Hoboken). 2011 Dec;63(12):1777-81. doi: 10.1002/acr.20605.

49.

Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Tomasson G, Boers M, Walsh M, LaValley M, Cuthbertson D, Carette S, Davis JC, Hoffman GS, Khalidi NA, Langford CA, McAlear CA, McCune WJ, Monach PA, Seo P, Specks U, Spiera R, St Clair EW, Stone JH, Ytterberg SR, Merkel PA.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):273-9. doi: 10.1002/acr.20649.

50.

Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.

Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, Spiera R, Sebastian JK, Davis JC Jr, St Clair EW, Allen NB, McCune WJ, Ytterberg SR, Specks U; Wegener's Granulomatosis Etanercept Trial Research Group.

Arthritis Rheum. 2011 Aug;63(8):2495-503. doi: 10.1002/art.30394.

Supplemental Content

Loading ...
Support Center